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Abstract: Maitake D-fraction or PDF is the bioactive extract of maitake mushroom (Grifola 
frondosa) and its active constituent is the protein-bound polysaccharide (proteoglucan), or 
more specifically known as β-glucan. PDF has been extensively studied and a number of its 
medicinal potentials/properties have been unveiled and demonstrated. Those include various 
physiological benefits ranging from immunomodulatory and antitumor activities to treatment 
for hypertension, diabetes, hypercholesterolemia, viral infections (hepatitis B and human 
immunodeficiency virus), and obesity. Particularly, two major biological activities of PDF, 
immunomodulatory and antitumor activities, have been the main target for scientific and clinical 
research. To demonstrate and confirm such biological activities, numerous studies have been 
performed in vitro and in vivo or in clinical settings. These studies showed that PDF was indeed 
capable of modulating immunologic and hematologic parameters, inhibiting or regressing the 
cancer cell growth, and even improving quality of life of cancer patients. Synergistic potentia-
tion of PDF with vitamin C demonstrated in vitro is rather interesting and may have clinical 
implication, because such combination therapy appears to help improve the efficacy of currently 
ongoing cancer therapies. Recently, intravenous administration of vitamin C has been often 
used to increase its physiological concentration and this useful procedure may further make 
this combination therapy feasible. Therefore, PDF may have great potential, either being used 
solely or combined with other agents, for cancer therapy. Such relevant and detailed studies 
will be described and discussed herein with a special focus on the combination of PDF and 
vitamin C as a viable therapeutic option.
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Introduction
Mushrooms have been known for centuries particularly among Chinese and Japanese 
people who consumed or utilized them for dietary or medicinal purposes. However, 
Western people have neither known these mushrooms nor gained their potential health 
benefits until recently. One reason for this disparity may arise from misunderstand-
ing or misconception about the nature and properties of mushrooms. As mushrooms 
belong to the family of “fungi”, many (Western) people have a general perception 
that mushrooms have little nutritional value while others think that eating mushrooms 
may make one vulnerable to some yeast infections. We now know these concepts are 
invalid, and to the contrary, mushrooms have great nutritional value including vita-
mins, minerals, amino acids, and fibers;1 they are indeed healthy food. As a number 
of mushrooms are now cultivated worldwide, their products or extracts have become 
easily available to the public and sold mainly as dietary supplements. The market International Journal of General Medicine 2009:2 92
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value of such mushroom supplement products worldwide is 
nearly US$5–6 billion annually.2
In addition to their dietary value, the medicinal aspects 
of mushrooms have been long appreciated in the Far East 
but are also rapidly gaining a great public attention in the 
Western world. Because of an easy and abundant availability 
of many mushrooms by cultivation, not only the public but 
also scientists can obtain them for scientific and clinical 
research. Bioactive extracts or metabolites of these medicinal 
mushrooms are widely being used to treat or prevent a variety 
of diseases. Since these mushroom products are considered 
as dietary supplements, they could be individually or person-
ally used for therapeutic purposes without going through a 
series of “phase trials” required for an ordinary drug/medicine 
under the US Food and Drug Administration (FDA). Yet, 
the sufficient scientific studies have not been performed on 
most of these mushrooms (or their products) to reveal and 
confirm their actual medicinal potentials/properties, although 
some of them have been indeed scientifically investigated. 
Particularly, one of them is known as “maitake mushroom” 
(Grifola frondosa) and its bioactive extract is named 
“Maitake D-fraction.”
Maitake D-fraction (PDF)
Maitake mushroom is a tasty edible mushroom. Maitake literally 
means “dancing mushroom”. It is a huge mushroom that can 
reach 20 inches in diameter and weigh up to 100 pounds. 
Besides its great taste, it has also been believed to provide 
health benefits and often used for therapeutic purposes. As 
maitake was then considered a medicinal mushroom, it has been 
extensively subjected to scientific studies for nearly 30 years 
which has revealed a number of medicinal properties that could 
provide remarkable health benefits. Various physiological ben-
efits of maitake have been postulated or demonstrated, ranging 
from immunomodulatory and antitumor activities to treatment 
for hypertension, diabetes, hypercholesterolemia, obesity, and 
hepatitis B infection.3–11 Its antiviral activity against human 
immunodeficiency virus (HIV)/AIDS was also confirmed by 
the US National Cancer Institute in 1992.12
The majority of maitake research described above 
has been performed using its bioactive extract, namely 
“Maitake D-fraction (PDF)”. This D-fraction or PDF is the 
protein-bound polysaccharide or proteoglucan, consisting 
of β-glucan (either β-1,6-linked glucan with β-1,3 branches 
or β-1,3-linked glucan branched with β-1,6 glucosides; see 
Figure 1) as a main polysaccharide backbone where a few 
uncharacterized protein units are attached to. In other words, 
PDF is not a pure form of β-glucan that is yet a core constitu-
ent but is a “proteoglucan” having both β-glucan (major) and 
protein (minor) portions. This is a huge proteoglucan with 
a molecular weight of ∼1 × 106 Daltons,3,13 having acid-
insoluble, alkali-soluble and hot water-extractable nature.3 
In addition, biological activities of PDF have been shown 
to stem primarily from β-glucan, which was thus considered 
a bioactive component of PDF.3,5,7,9–13 Particularly, its two 
major biological activities, such as immunomodulatory and 
antitumor activities,3,7,13 have been well documented and its 
clinical and therapeutic utilities are known.
Immunomodulatory activity of PDF
The innate immune system is the first line of defense against 
microbial invasion, which immediately recognizes and copes 
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with such infections. Although various β-glucans have been 
known to commonly exhibit immunomodulatory activity 
for a long time,14 such underlying cellular and molecular 
mechanisms have not been fully defined but were recently 
being unveiled. Since PDF has a core β-glucan structure for 
its inherent bioactivities, all immunomodulatory activities 
demonstrated with β-glucans would be substantially relevant 
to those exhibited by PDF. Such immunomodulations by 
β-glucans include mitogenecity and activation of immune 
effector cells such as lymphocytes, macrophages, dendritic 
cells, and natural killer (NK) cells, stimulating the production 
of various cytokines and chemokines such as interleukins 
(IL-1β, IL-6, IL-8, IL-12 etc.), tumor necrosis factor-α 
(TNF-α), and interferon-γ (IFN-γ).15,16 However, the first step 
in triggering the immune-modulating effects by β-glucans 
requires the specific cellular receptors that recognize and 
bind to them. In fact, a number of “β-glucan receptors” 
have been identified on both immune and nonimmune cells, 
including macrophages, NK cells, monocytes, neutrophils, 
endothelial cells, fibroblasts, etc.17 Those receptors include 
complement receptor 3 (CR3), lactosylceramide, scavenger 
receptors, and Dectin-1.18 Particularly, Dectin-1 appears to 
be the most interesting receptor, predominantly found on 
macrophage/monocyte and neutrophil lineages, and can 
recognize soluble and particulate β-glucans.19 It then medi-
ates a variety of cellular immune-modulating effects, such 
as phagocytosis, endocytosis, and the oxidative burst, and 
also induces the production of pro-inflammatory cytokines/
chemokines including TNF-α, IL-12, and macrophage-
inflammatory protein-2 (MIP-2)18,20 although they could work 
paradoxically in a positive or negative manner, depending on 
microenvironments where they are regulated or interact with 
certain/specific factors. Nevertheless, β-glucans would acti-
vate a wide variety of innate host defenses, such as protection 
against infections with fungal, protozoal, bacterial, and viral 
pathogens, as well as prevention/protection against cancer 
development (carcinogenesis). This may well represent how 
various β-glucans or PDF would induce the immunomodula-
tory effects: ie, binding of β-glucans to specific receptors, 
triggering activation of immune effector cells, stimulating 
production of cytokines/chemokines, and targeting and 
attacking foreign pathogens and (cancer) cells.
The following studies describe various immunologic 
and hematologic aspects of PDF; however, it should be 
noted that PDF used in some of those studies were essen-
tially all the same but not exactly the same or identical, due 
to changes in suppliers/manufacturers of PDF or maitake 
extracts during the past 30 years. Nevertheless, all data 
obtained from the studies used PDF or “similar maitake 
extracts” are fully relevant.
effects of maitake extract on hematopoietic stem cells
Recently, the effects of the maitake extract similar to PDF have 
been reported on mouse bone marrow cells (BMCs), describing 
that this extract was capable of enhancing BMC proliferation 
and differentiation into granulocytes-macrophages (GMs).21 
In addition, the extract protected the colony formation unit 
(CFU) response of GMs (CFU-GM response) from doxorubi-
cin (DOX)-induced hematopoietic suppression.21 The similar 
results were also obtained from the separate study using human 
umbilical cord blood (CB) cells: the extract induced differen-
tiation of CB cells into CFU-GM and reduced DOX-induced 
hematopoietic toxicity.22 Thus, these results suggest that mai-
take extract may have such a potential to induce hematopoietic 
cell differentiation and protect those cells from the toxic effects 
exerted by chemotherapy. In particular, this maitake extract or 
PDF may have clinical implications in treatment of myelosup-
pression and other hematopoietic disorders/diseases.
effects of PDF on immune system in vitro or in vivo
To assess the actual effects of PDF on the immune system 
or its immunomodulatory activity, a number of studies have 
been conducted in vitro (cell cultures) as well as in vivo 
(animals and humans).
As PDF has been believed to have antibacterial activity 
by stimulating the host immune system, its possible effects 
on the treatment of Listeria-infected mice in combination 
with vancomycine (VCM) has been investigated. Listeria 
monocytogenes are the gram-positive, food-mediated 
bacteria, causing the listeria,23 and VCM is usually the 
primary therapeutic modality but its high dose is known to 
cause various side effects. It is then feasible if the VCM dose 
could be reduced once combined with PDF, alleviating side 
effects while improving the efficacy. Such studies showed 
that the survival rate of Listeria-infected mice treated with the 
PDF/VCM combination was longer/better (60% on the 10th 
day) than those treated with VCM alone, while non-treated 
control mice died in three days after the inoculation.24 It was 
also found that macrophages in PDF/VCM-treated mice 
produced 2.7 times as much IL-1 as that of nontreated control 
mice. The bactericidal activity of T cells was also 2.6 times 
greater than that of control mice. Thus, these findings sug-
gest an adjuvant role of PDF in antibacterial treatment for 
patients in a high risk group.
The recognition of microbes by macrophages would lead 
to phagocytosis, activating several enzymes including the International Journal of General Medicine 2009:2 94
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inducible nitric oxide synthase (iNOS) that facilitates the 
production of bactericidal reactive oxygen intermediates 
and nitric oxide (NO).15 Such activation of iNOS with NO 
production is considered the macrophage-mediated immune 
response. Accordingly, the effects of PDF has been exam-
ined on iNOS-mediated NO production in RAW264.7 cells, 
a murine macrophage cell line. PDF was shown to induce 
iNOS-mediated NO production by RAW cells, which then 
significantly reduced the cell viability of human hepatoma-
derived huH-1 cells.25 This antitumor effect of RAW cells 
is thus due to activation of iNOS by PDF, not to direct 
cytotoxic activity of PDF on huH-1 cells, demonstrating the 
macrophage-mediated antitumor effect.
In the early animal studies, PDF has demonstrated 
immune enhancement in tumor-bearing mice: immune 
effector cells and cytokines such as NK cells, T lymphocytes 
(CTL), lymphokine-activated killer cells, IL-1 and IL-2 
were all activated by 1.5–2.2-fold (compared to controls) 
following the PDF treatment26 (Table 1). Concurrently, the 
rate of cancer proliferation was significantly reduced with 
PDF, demonstrating its antitumor activity. These results thus 
suggest that PDF appears to be a potent immunomodulator, 
which is also capable of reducing or slowing down the cancer 
cell growth through its immune-modulating effects.
NK cells are a class of lymphocytes that rapidly respond 
to intracellular infections with viruses or bacteria, killing 
those infected cells and producing the macrophage-activating 
cytokines. However, NK cells do not express T-cell recep-
tors that recognize specific peptides presented on the major 
histocompatibility complex (MHC), but they can recognize 
the surface changes that occur on infected cells or a variety of 
cancer cells.27 NK cells are also known to have two relevant 
functions.28 One of them is cytotoxicity, mediated through 
the recognition and lysis of target cells such as virus- or 
bacteria-infected cells. The other function is to produce 
various cytokines such as IFN-γ, TNF-α, and granulocyte/
macrophage-colony-stimulating factor (GM-CSF), which can 
modulate natural and specific immune responses. Such stud-
ies focusing on NK cells, ie, the effects of PDF on NK cells, 
have been performed in cancer patients and mice. A limited, 
noncontrolled clinical trials of PDF on eight cancer patients 
showed that cytotoxic activity of NK cells in these patients 
were elevated by 1.2–2.7 times with the PDF treatment and 
such elevated levels were even maintained for one year.29 
To elucidate the mechanism of sustained NK activity with 
PDF, studies using mice and cell cultures were also per-
formed. C3H/HeN mice were implanted with MM-46 breast 
carcinoma cells and received PDF intraperitoneally (i.p.) for 
19 days. The levels of TNF-α and IFN-γ released from spleen 
cells and TNF-α expression in NK cells were significantly 
increased in tumor-bearing mice received PDF (compared 
to control mice without PDF), as their tumor growths were 
markedly suppressed.29 This increased TNF-α and IFN-γ 
release is typically indicative of activation of NK cells. 
Moreover, the increased IL-12 secretion from macrophage 
RAW 264.7 cells was also demonstrated following the PDF 
treatment.29 Since IL-12 is critical to the functions of NK and 
T cells, the long-term NK cytotoxicity with PDF could be 
at least in part attributed to the increased IL-12 release from 
macrophages. NK cells could be further activated by IFN-γ 
released from themselves as well as activated T cells. Simi-
larly, in separate study activation of peripheral blood NK cells 
and their sustained cytotoxicity with PDF was observed in 
patients with lung, breast, and liver cancer.30
Besides the innate immune response primarily involving 
NK cells and macrophages, there is another one called the 
adaptive immune response that comprises T and B cells. 
T cells or CTL include T-helper (Th) cells and cytotoxic 
T (Tc) cells. Th cells activate B cells to secrete antibodies 
targeting foreign antigens (known as the antibody response), 
while Tc cells attack and destroy infected host cells with 
pathogens (as the cell-mediated immune response).31 Th cells 
can be also classified into Th-1 and Th-2 cells according 
to the types of cytokines they produce. Th-1 cells produce 
IL-2, IFN-γ, and TNF-β (introducing cellular immunity to 
the organisms), while Th-2 cells produce IL-4, IL-5, IL-6, 
IL-10, and IL-13 (activating humoral immunity).32 One study 
showed that PDF decreased B cell activation but increased 
Th-1 cell activation in tumor-bearing C3H/HeN mice, result-
ing in enhanced cellular immunity. PDF also stimulated the 
production of IFN-γ, IL-12p70, and IL-18, but suppressed 
IL-4 production.33 These results then suggest that PDF may 
Table 1 effects of PDF on immune effector cells and cytokines in 
tumor-bearing mice
Immune effector 
cells/cytokines
Activation by PDF administration  
(Relative to Controla value of 1.00)
NK cells 1.52
CTL 2.22
Lymphokine-activated 
killer cells
1.64
IL-1 1.98
IL-2 1.73
Note: aSaline injection.
Abbreviations: NK, natural killer; CTL, cytotoxic T lymphocytes; IL-1, interleukin 1; 
IL-2, interleukin 2; PDF, Maitake D-fraction.International Journal of General Medicine 2009:2 95
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establish Th-1 dominance that induces cellular immunity in 
the population with Th-2 dominance due to carcinoma.
It was yet of interest to perform the same study above 
using “BALB/c” mice (instead of C3H/HeN mice), because 
they have been genetically altered to have a “Th-2” dominant 
response. Such study then revealed that PDF was capable of 
inducing the differentiation of tumor-bearing BALB/c mice 
with the Th-2 response into the Th-1 dominant response, medi-
ated through enhancement of IL-12p70 production by dendritic 
cells (DCs), which were antigen-presenting cells (APCs) with 
a unique ability to activate both Th and Tc cells and produce 
IL-12 and INF-γ.34,35 These results thus suggest that PDF 
may stimulate DCs, through activation of macrophages and 
NK cells, inducing innate T cells into Th-1 cells.
effects of maitake extract or PDF on immunologic 
or hematologic parameters in cancer patients 
or normal subjects in controlled clinical trials
It has been recently reported that the maitake extract (similar 
to PDF) was used in a phase I/II trial of breast cancer patients 
to assess its immunologic effects. Thirty-four postmeno-
pausal breast cancer patients, free of disease after the initial 
treatment, followed an oral regimen of this maitake extract 
for three weeks and various immunologic parameters were 
analyzed.36 No apparent toxicity of the extract was observed 
but there was a statistically significant association between 
the extract and immunologic function: some immunologic 
parameters were upregulated with the extract while others 
were downregulated. For example, depending upon the dos-
age of the extract given, CD3+/CD25+, CD4+/CD25+, IL-2, 
or IL-10 was significantly increased but IFN-γ production 
was decreased. This is indicative of the modulation of cell-
mediated immunity with the extract. Thus, these results show 
that oral administration of this extract indeed modulates 
immunologic parameters in these cancer patients, so that 
they should be aware that it could stimulate as well as depress 
their immune function.
This study may then raise the question on how such 
maitake extract or PDF would affect “healthy individuals”, 
and such study has been also conducted. Twenty-eight 
healthy subjects participated in a randomized double-blinded 
trial of PDF for one month. Various hematologic param-
eters including complete blood count, serum glucose, total 
cholesterol and high-density lipoprotein (HDL), bilirubin, 
creatinin, hepatic enzymes, etc. were evaluated before and 
after a one-month PDF regimen.37 All hematologic data were 
subjected to statistical analysis and summarized in Table 2. 
First of all, no participants presented palpable ailments or 
adverse effects during the trial. Second, no substantial and 
clear differences/changes in 24 parameters tested were seen 
between the control and the PDF groups after this one-month 
trial. However, significant statistical differences (p  0.05) 
in hemoglobin, hematocrit, eosinophils, mean corpuscu-
lar volume (MCV), cholesterol, triglycerides, creatinin, 
alkaline phosphatase, glutamic-pyruvic transaminase/alanine 
aminotransferase (GPT/ALT), and glutamic-oxaloacetic 
transaminase/aspartate aminotransferase (GOT/AST) were 
seen in between the PDF and placebo groups. In addition, 
although the differences may not be clearly significant, 
those in red blood cells (RBC), lymphocytes, mean corpus-
cular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), and HDL were yet nearly statisti-
cally significant (0.05  p  0.1). Moreover, there was the 
Table 2 effects of PDF on hematological parameters in human 
subjects
Parameters Placebo vs PDF Statistical 
significance
rBC count p = 0.082 N/S
wBC count p  0.1 N/S
Hemoglobin p  0.05 Significant
Hematocrit p  0.05 Significant
Lymphocytes p = 0.082 N/S
Platelets p  0.1 N/S
Monocytes p  0.1 N/S
Granulocytes (eosinophil) p  0.05 Significant
Granulocytes (neutrophil) p  0.1 N/S
Granulocytes (basophil) p  0.1 N/S
MCv p  0.05 Significant
MCH p = 0.059 N/S
MCHC p = 0.081 N/S
Glucose p  0.1 N/S
Cholesterol (total) p  0.05 Significant
HDL p = 0.082 N/S
Triglycerides p  0.05 Significant
Creatinin p  0.05 Significant
Alkaline phosphatase p  0.05 Significant
GPT/ALT p  0.05 Significant
GOT/AST p  0.05 Significant
Bilirubin p = 0.051 N/S
Transferrin p = 0.068 N/S
Iron p  0.1 N/S
Abbreviations: N/S, not significant; RBC, red blood cell;   WBC, white blood cell; MCV, 
mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpus-
cular hemoglobin concentration; HDL, high-density lipoprotein; GPT, glutamic-pyruvic 
transaminase;   ALT, alanine aminotransferase; GOT, glutamic-oxaloacetic transaminase; 
AST, aspartate aminotransferase; PDF, Maitake D-fraction.International Journal of General Medicine 2009:2 96
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possible time trend (prediction) that the differences in some 
parameters could become significant in the long term (ie, 
longer than one month of this trial). One may then speculate; 
for example, the decreased creatinin concentration (p  0.05) 
with PDF could indicate the improved renal function, while 
the reduced levels of GPT/ALT and GOT/AST indicate 
the improved liver function with the reduced hepatic cell 
injury. Similarly, the decreased cholesterol and triglyceride 
levels (p  0.05) could be indicative of the improved lipid 
metabolism, preventing potential adverse sequels associated 
with cardiovascular disease. Apart from these speculations, 
this study yet confirms that PDF undoubtedly has certain 
hematologic effects on normal subjects and larger random-
ized studies are thus required for demonstrating its potential 
health benefits.
Antitumor/anticancer activity of PDF
Peculiarly it has been known that many mushroom extracts 
were ineffective when given orally to animals bearing cancers, 
although they could be effective or exhibit antitumor activity 
when administered intravenously or intraperitoneally.38 
However, a number of studies have then demonstrated anti-
tumor activity of orally administered PDF in vivo, which 
was mainly associated with its immunomodulatory activity 
described above.
When an allogeneic Sarcoma-180 tumor was implanted 
into ICR-nu/nu mice (lacking matured T cells), orally admin-
istered PDF was capable of inhibiting the tumor growth by 
88% compared to control mice (no PDF received).39 The 
similar results were also obtained from the studies using 
different mice bearing some syngeneic tumors. Following 
oral PDF administration, C3H/HeN mice bearing MM-46 
carcinoma (breast cancer), CDF1 mice with IMC carcinoma 
(skin cancer), and C57BL/6 mice with B-16 melanoma (skin 
cancer) showed tumor inhibition of 64%, 75%, and 27%, 
respectively.39 These results are summarized in Table 3. It 
is thus practical that oral administration of PDF would allow 
us its easy intake for a clinical utility.
Another interesting study was to assess whether PDF 
might prevent carcinogenesis (cancer development) in nor-
mal cells, ie, anticarcinogenic activity. A known carcinogen, 
N-nitrosodi-n-butylamine (NDBA), was given to mice with 
food: the control group received only normal feed (with 
NDBA) while the PDF group received food (with NDBA) 
and oral PDF supplement. After 60 days, the number of 
tumors appearing or developing in the liver was determined. 
The cancer incidence rate in the PDF group was merely ∼10% 
compared to that in the control group (100% as the number 
of cancer cells found).40 A similar study using another known 
carcinogen, 3-methylcholanthrene (3-MCA), on mice has 
been also conducted. An injection of 3-MCA (suspended in 
olive oil) was given to the back of mice (n = 10/group) once, 
and PDF or saline solution (control) was orally administered 
on the 15th day for 15 consecutive days. After 30 days, the 
number of mice with cancer was ∼93% in the control group 
but only 31% in the PDF group.41 These findings suggest that 
PDF appears to significantly prevent carcinogenesis or may 
have anticarcinogenic activity.
A critical issue following carcinogenesis is to slow down 
cancer progression or inhibit cancer metastasis, and such 
antimetastatic activity of PDF has been also investigated 
using tumor-bearing mice. MM-164 liver carcinoma was 
injected into the left rear footpad of mice, which was then 
amputated after two days. Either normal food alone (control) 
or that with PDF was given to (amputated) mice daily, and 
after 30 days the number of tumor foci metastasized to the 
liver was determined. Compared to the control group, cancer 
metastasis to the liver was remarkably prevented by over 
90% in the PDF group.40 In another study, MM-46 breast 
carcinoma was intraperitoneally implanted in C3H/HeN 
mice and subsequently the palpable tumor formed (∼7 mm 
in diameter) was surgically removed. PDF or saline (control) 
was then given to mice for 10 consecutive days and the tumor 
foci spread to other organs were assessed in sacrificed mice. 
The tumor metastasis (the number of metastasized tumor foci 
found) was inhibited by 92% in the PDF group whereas no 
such inhibition (0%) was seen in the control group.41 Thus, 
PDF may have antimetastatic activity (preventing tumor 
metastasis), presumably activating immune-competent cells 
that would then necrotize tumor cells present in the blood 
and/or lymphatic vessels.
Moreover, it has been reported that the combination of 
PDF and mitomycin C (MMC), a chemotherapeutic drug, 
exhibited the augmented antitumor activity in vivo. In this 
Table 3 Antitumor effect of PDF on tumor-bearing mice
Tumor system Mice Growth inhibition  
(% relative to control)
Allogeneic tumor
Sarcoma 180 ICr-nu/nu 88%
Syngeneic tumors
MM-46 breast carcinoma C3H/HeN 64%
IMC skin carcinoma CDF1 75%
B-16 melanoma C57BL/6 27%
Abbreviations: PDF, Maitake D-fraction.International Journal of General Medicine 2009:2 97
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study, tumor-bearing mice received PDF alone showed the 
greater tumor growth inhibition (∼80%) than that (∼30%) 
in those received MMC alone. When PDF and MMC were 
given together (by cutting each initial dose by half) to mice, 
the tumor growth was almost completely (98%) inhibited.26 
Such enhanced antitumor effect of PDF and MMC might be 
explained by the stimulated immune response with PDF (as an 
immunomodulatory) and by a direct cytotoxic effect of MMC 
on tumor cells. Thus, it is plausible that PDF could be used as 
an adjuvant agent for chemotherapy in cancer patients.
Clinical trials of PDF on cancer patients
Regarding clinical trials of PDF, not many human trials have 
been performed and only a few information are available. 
Yet, a nonrandomized clinical study of PDF on 165 patients 
with various types of advanced cancers has been conducted in 
Japan.26 Such study showed that tumor regression or significant 
symptomatic improvements with PDF were observed in 73% 
of breast cancer patients, 67% of lung cancer patients and 47% 
of liver cancer patients. When PDF was given to the patients 
receiving chemotherapy, the response rates have improved from 
12% to 28%. Overall, this study illustrated that the clinical status 
of patients with breast, prostate, lung, and liver cancers was 
significantly improved with PDF, while less effective on those 
with bone and stomach cancers or leukemias.26,42 In addition, 
interestingly various side effects of chemotherapy on all types 
of cancer patients were ameliorated with PDF administration. 
It is well known that chemotherapy often lowers or damage the 
immune system, but PDF may help maintain optimal activities 
of key immune-competent cells, minimizing such side effects. In 
fact, adverse symptoms such as nausea, hair loss, and leukopenia 
have been alleviated in 90% of those patients, while a reduction 
in pain was reported in 83% of patients.26 Thus, PDF appears 
to improve quality of life in patients and might be considered a 
useful adjuvant in ongoing cancer chemotherapy.
In addition, following PDF having been exempted from a 
phase I toxicology test by the FDA in early 1990’s, it has been 
also approved for the investigational new drug (IND) applica-
tion for a phase II pilot study on patients with advanced breast 
and prostate cancer.43 Among the ongoing FDA-sanctioned 
PDF studies on prostate cancer patients, it would be worth-
while briefly mentioning some of prostate cancer cases.44 
The patients with prostate cancer have orally received the 
appropriate amounts (calculated from the body weight) of 
PDF daily with 2,000 mg vitamin C (VC) and were evaluated 
for general condition, blood chemistry, and immune status 
(eg, activities of NK cells and CTL). Additionally, the levels 
of serum prostate-specific antigen (PSA), a widely used 
biochemical marker for prostate cancer, were measured for 
assessing the disease status of these patients.
Case 1
A 68-year-old patient was diagnosed for prostate cancer with 
the initial PSA of 20 ng/ml (a normal PSA range: 4.0 ng/ml) 
in 1998. His PSA steadily went up every year till 2000, indi-
cating a possible progression of disease. After he started tak-
ing PDF with VC in 2001, his PSA came down significantly 
in three months and all other parameters looked also stable 
since then. Thus, this report suggests that cancer progression 
might have been slowed down or stopped by PDF.
Case 2
The initial PSA of 7 ng/ml (in 1995) in a 72-year-old patient 
declined to 1.7 ng/ml by 2000 following primary hormonal 
therapy. He appeared to be in disease remission, but his PSA 
started rising again in June of 2001 and went up further to 
3.9 ng/ml by September, indicating a possible recurrence or 
progression of cancer. He was placed immediately in a PDF 
regimen and his PSA gradually came down to 2.2 ng/ml by 
three months. This report also suggests that PDF may slow 
down or stop cancer progression.
Case 3
This is rather an interesting case with a high Gleason score of 
7 (while PSA was 8 ng/ml) in a 65-year-old patient. “Gleason 
score” is a pathological grading system of 1–10 based on the 
histological examination of biopsy specimen,45 helping us 
assess a probability of having cancer metastasis: in general, 
the higher score indicates the greater risk of metastasis. Since 
his initial PSA had not notably come down in two years, he 
decided to have a surgery (radical prostatectomy) in 2001. 
His PSA went down significantly to 2 ng/ml in a month 
after his surgery, although we were yet concerned about 
possible metastasis because of his high Gleason score. As a 
precaution, he then started taking PDF and his PSA further 
declined to 0.1 ng/ml in six months. His prognosis was 
good with all parameters being normal. This report suggests 
that PDF may also suppress metastatic disease or stop cancer 
progression to a fatal hormone-refractory state, although it 
is possible that surgery could have completely removed the 
tumor before metastasis started up.
These case studies suggest that PDF may help lower the 
serum PSA levels in prostate cancer patients and probably 
slows down or prevents disease progression or metastasis. 
We also found that PDF appeared to sustain the high levels 
of NK cell and CTL activities, indicating an alert immune 
surveillance, and to improve physical/mental soundness and International Journal of General Medicine 2009:2 98
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quality of life of these patients. Taken all together, PDF is 
indeed safe to cancer patients (as well as healthy subjects37) 
and may also offer some health benefits, comfort, and hope 
to those patients.
Synergistic potentiation of PDF 
with vitamin C
Vitamin C (VC) or ascorbic acid could be the most popular 
nutritional supplement known and taken by numerous people. 
VC is a water-soluble antioxidant that can scavenge free radi-
cals, thereby protecting the cells from lethal oxidative stress.46 
Interestingly, VC may also act as a pro-oxidant to generate free 
radicals, particularly through the reduction of metal ions such 
as iron or copper: this is known as the Fenton reaction.47 In 
other words, VC has a dual role that can act as an antioxidant 
or a pro-oxidant, depending upon its (high) cellular concentra-
tions and the availability/presence of cellular iron.
Besides such redox properties of VC, it has been well 
documented that VC also had anticancer effect on various 
cancer cells in vitro, due to its pro-oxidant activity to gener-
ate free radical (hydrogen peroxide, H2O2) rather than its 
popular antioxidant action.48 Yet, another important ques-
tion is whether VC would be able to actually induce such 
generation of free radicals (particularly H2O2) in vivo. It has 
been then shown that a measurable or significant amount of 
H2O2 was indeed generated with the high concentrations of 
VC achieved through its intravenous (i.v) administration in 
mice.49 Such a mechanism(s) is not completely understood 
but it may likely involve or interact with some protein-bound 
metal cations. In addition, this VC-mediated H2O2 production 
in vivo appears to only take place in extracellular fluids, not 
in blood, since antioxidant enzymes (eg, catalase, glutathione 
peroxidase, etc.) present in erythrocytes could efficiently 
remove or scavenge H2O2.50 VC has been also reported to 
promote the efficacy of several chemotherapeutic drugs 
in vivo;51 however, the oral administration of VC (6,100 mg) 
had no effects on patients undergoing chemotherapy52 and 
even the higher VC dose (10 g) was ineffective on patients 
with advanced cancer.53 Moreover, pharmacokinetic stud-
ies revealed that the oral administration of VC would not 
achieve its plasma concentrations higher than 50–100 µM.54 
However, the phase I trial of the iv administration of VC to 
cancer patients has reported that the high-dose VC instillation 
demonstrated anticancer effect. In this study, the iv infusion 
of VC allowed an injection of the extremely high VC doses 
up to 1.5 g/kg (body weight) in cancer patients, raising their 
plasma concentrations 10 mM for over four hours, which 
have been previously shown to be sufficient to induce cancer 
cell death in vitro.55 This new approach of iv administration 
of VC to achieve its therapeutic (effective) plasma level as 
an adjuvant therapy is becoming popular but yet remains 
controversial in the absence of sufficient and reliable clinical 
data. Thus, further clinical studies are warranted to collect 
more data to adequately address the true efficacy of VC in 
cancer therapy.
Synergism: enhanced PDF activity with vC
Apart from various aspects of VC described above, it was 
rather interesting for us to learn that VC had been postulated 
to enhance bioactivity of mushroom extract or specifically 
β-glucans,56 although the exact mechanism needs to be yet 
defined. Since PDF has β-glucan as its major bioactive 
element mentioned earlier and could be potentiated with 
VC, it was reasonable that VC had been included in the 
PDF regimen for prostate cancer patients described above, 
although the actual effects of VC with PDF have not yet been 
addressed. To examine such combined effects of PDF and VC 
on cancer cells, we performed the in vitro study using human 
prostate cancer PC-3 cells as our experimental model. This 
study has been published previously,57 but it should be noted 
that making the concentrations of PDF used in all studies 
comparable or relevant, these values have been normalized 
in the following studies described because the stock PDF 
concentrations had varied with some modifications made on 
formulating PDF by the manufacturer.
effects of PDF or vC on PC-3 cell growth
Prostate cancer is the second-leading cause of cancer death in 
elderly men in the United States. Although several conven-
tional therapies including androgen ablation, chemotherapy, 
brachytherapy (radioactive seeds implant), radiotherapy, immu-
notherapy, surgery, etc. are currently available, none of them 
has yet been able to achieve the expected level of efficacy.58,59 
Thus, exploring and establishing a more effective modality for 
prostate cancer treatment is urgently demanded. As an alter-
native unconventional approach, we examined if PDF might 
inhibit or slow down the growth of human prostate cancer PC-3 
cells, derived from a patient with bone metastasis.60
PC-3 cells were cultured with the varying concentrations 
(0–1,000 µg/ml) of PDF and cell number and viability were 
assessed in 72 h. This dose-response study showed that no 
effects of PDF was seen up to 250 µg/ml but a marginal 
(∼15%) and significant (∼65%) growth reduction was observed 
at 500 and 1,000 µg/ml, respectively (Figure 2). When cells 
were cultured with a varying concentration (0–1,000 µM) of 
VC, no apparent effects were seen up to 300 µM, a little over International Journal of General Medicine 2009:2 99
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50% reduction in cell viability was attained with 500 µM, and 
nearly complete cell death (∼0% cell viability) was observed 
with 1,000 µM in 72 h (Figure 3). Thus, these results show that 
PDF is capable of inhibiting cell growth at a high concentra-
tion and VC appears to also induce significant cell death at its 
concentrations 500 µM.
Synergistic effects of PDF combined  
with vC on PC-3 cell growth
Since it would be practical if such a high concentration of 
PDF required could be somehow lowered without losing its 
potency, we next examined whether VC might help aug-
ment PDF potency as it has been postulated above.56 PC-3 
cells were treated for 24 h with the relatively low, ineffective 
concentrations (0–250 µg/ml) of PDF (Figure 2) in combination 
with the similarly ineffective concentrations (0–200 µM) 
of VC (Figure 3). Among various combinations tested, par-
ticularly the combination of 150 µg/ml PDF and 200 µM VC 
resulted in 90% cell death in 24 h (Figure 4). Since neither 
150 µg/ml PDF nor 200 µM VC alone showed any effects on 
cell growth/viability, the resulting 90% cell death induced 
with this particular PDF/VC combination is more likely attrib-
uted to a synergistic potentiation of these two agents. It is then 
plausible that VC may primarily serve as an adjuvant factor to 
augment the PDF activity. Therefore, this finding is significant 
and suggests that the relatively low concentrations of PDF with 
no cytotoxic activity could be yet synergistically potentiated 
with VC to become highly cytotoxic to PC-3 cells.
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Figure 2 effect of PDF on PC-3 cell growth. PC-3 cells were cultured with the varying concentrations of PDF (0–1,000 µg/ml), and viable cell numbers were determined in 
72 h. All data represent mean ± SD from three separate experiments.
Notes: *p  0.02; **p  0.08.
Abbreviations: PC-3, human prostate carcinoma cell line; PDF, Maitake D-fraction; SD, standard deviation.International Journal of General Medicine 2009:2 100
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Oxidative stress exerted by PDF/vC combination
To explore the cytotoxic mechanism of the PDF/VC 
combination, possible involvement of oxidative stress 
(generation of free radicals) was investigated. We observed 
“cell blebbing” (cytoplasmic vesicle formation) in PC-3 cells 
treated with the PDF/VC combination (data not shown), 
which was indicative of the cells under oxidative stress.61 
As mentioned earlier, cytotoxic activity of VC in vitro has 
been shown and believed to be associated with oxidative 
stress, particularly generation of H2O2.48 Accordingly, 
lipid peroxidation (LPO) assay was performed on the cells 
exposed to the combination of PDF (150 µg/ml) and VC 
(200 µM) for merely three hours, which should have been 
sufficient to exert oxidative stress. This PLO assay has been 
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Figure 3 effect of vC. PC-3 cells were cultured with the indicated concentrations of   vC, and viable cell numbers were determined in 72 h.   All data are mean ± SD from three 
independent experiments.
Note: *p  0.05.
Abbreviations: PC-3, human prostate carcinoma cell line; SD, standard deviation;   vC, vitamin C.International Journal of General Medicine 2009:2 101
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often used for assessing possible damage or perturbation in 
the plasma membrane due to oxidative stress, by measur-
ing the amount of malondialdehyde (MDA) formed, an end 
product from peroxidation of polyunsaturated fatty acids in 
the plasma membrane.62 Such analyses then revealed that the 
LPO level in PDF/VC-exposed cells was almost two-fold 
higher than those in control, sole PDF- or sole VC-exposed 
cells (Figure 5). This finding indicates that significant plasma 
membrane damage has occurred in PDF/VC-exposed cells, 
mediated through severe oxidative stress, causing cellular 
turmoil and ultimately leading to cell death.63 Thus, these 
results support the notion that PDF/VC-induced cell death is 
at least in part due to oxidative stress, presumably through 
H2O2 generated.
However, one may raise some concern for a clinical utility 
of PDF/VC combination because their cytotoxic mechanism 
appears to be primarily attributed to oxidative stress. It is 
conceivable that such resulting oxidative stress could cause a 
nonspecific random damage to even normal cells (as well as 
cancer cells). Interestingly, it has been shown that cancer cells 
were generally more vulnerable to oxidative stress than normal 
cells.64 Although the reason(s) for a different susceptibility of 
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Figure 4 effects of PDF/vC combination on cell viability. PC-3 cells were treated for 24 h with the ineffective concentrations (0–250 µg/ml) of PDF in combination with the 
similarly ineffective concentrations (0–200 µM) of   vC. Particularly, the combination of 150 µg/ml PDF and 200 µM vC resulted in 90% cell death (*p  0.01) as shown here.
Abbreviations: PC-3, human prostate carcinoma cell line; PDF, Maitake D-fraction;   vC, vitamin C.International Journal of General Medicine 2009:2 102
Konno Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
these cells is not fully understood, several evidences suggest 
that it may result from the inherent difference in antioxidant 
enzymes whose primary function is to scavenge harmful free 
radicals. For example, two common antioxidant enzymes, 
catalase and glutathione peroxidase, have been found to be 
often deficient or have a significantly low activity in cancer 
cells.65 Thus, a difference in cellular antioxidant enzymes 
may at least account for a different susceptibility of normal 
and cancer cells to oxidative stress. It is then plausible that 
oxidative stress exerted by the PDF/VC combination could 
be high or severe enough to kill cancer cells but might not 
be severe enough for normal cells because those free radicals 
could be effectively scavenged by active antioxidant enzymes. 
As a result, oxidative stress exerted by the PDF/VC combina-
tion would likely kill cancer cells whereas normal cells may 
remain safe and intact. Therefore, the PDF/VC combination 
appears to effectively and selectively target cancer cells, 
implying their clinical/therapeutic utility.
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Figure 5 Assessment of lipid peroxidation (LPO) level with PDF/vC combination. Cells were exposed to the combination of PDF (150 µg/ml) and vC (200 µM) for merely 
3 h, and the LPO levels in control, PDF alone-, vC alone-, and PDF/vC-exposed cells were determined for comparison, by measuring the amount of malondialdehyde (MDA) 
formed. The data are mean ± SD from three separate experiments.
Notes: *p  0.01.
Abbreviations: PDF, Maitake D-fraction; SD, standard deviation;   vC, vitamin C.International Journal of General Medicine 2009:2 103
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 A) Control 
B) PDF/VC-treated 
Figure 6 In situ hybridization assay. Cells were treated with the combination of PDF 
(150 µg/ml) and vC (200 µM) for 24 h and evaluated for apoptosis using ISH assay. 
A minimum of 100 cells from control and PDF/vC-treated cells were counted and 
assessed for staining. Over 90% (92/100) of PDF/vC-treated cells (B) were positively 
stained (with brown color), while 90% (93/100) of control cells (A) were negative 
for a stain (giving off green color).
Abbreviations: PDF, Maitake D-fraction;   vC, vitamin C.
Induction of apoptosis by PDF/vC combination
The next valid question is exactly how PC-3 cells would die 
from the PDF/VC treatment, whether they may die with necro-
sis or apoptosis (programmed cell death). Despite a drastic 
reduction (90%) in cell viability induced by the PDF/VC 
combination, cell fragmentation or disintegration was rarely 
observed, indicating that such cell death would be unlikely 
due to necrosis. Accordingly, we performed in situ hybridiza-
tion (ISH) assay to test possible induction of apoptosis by the 
PDF/VC combination. ISH analyses then revealed that the 
cells treated with the combination of PDF (150 µg/ml) and 
VC (200 µM) for 24 h exhibited a positive brown staining 
(Figure 6B) while a negative staining was seen in control cells 
(Figure 6A). Since distinctly fragmented DNA can be stained 
(giving off brown color) with ISH assay, its positive staining 
is indicative of apoptotic cell death.66 Thus, these results sug-
gest that PDF/VC-induced cell death most likely results from 
apoptosis or follows the apoptotic pathway.
Combined effects of PDF 
and chemotherapeutic drugs
It was of interest to further examine whether cytotoxic activ-
ity of PDF/VC combination could be comparable to that of 
chemotherapeutic drugs, and VC or PDF might also act as the 
adjuvant agents to potentiate those drugs. As prostate cancer 
has been known to be highly resistant to chemotherapy,67 it 
would be certainly beneficial if such a poor efficacy of these 
drugs could be somehow improved.
Accordingly, PC-3 cells were treated solely with 
various chemotherapeutic drugs, including vinblastine 
(VBL), 5-fluorouracil (5-FU), methotrexate (MTX), etoposide 
(VP-16), cisplatin (CPL), cyclophosphamide (CyP), mitomy-
cin C (Mit.C), and carmustine (BCNU), or in combination with 
VC (200 µM) or PDF (150 µg/ml). To attain the optimal effi-
cacy of each drug in vitro, the concentrations of drugs used here 
were the estimated maximum or above physiologically toler-
able levels. Cell viability at each condition was then assessed 
in 72 h and the results are summarized in Table 4. However, 
as VC was found to have no effects on improving cytotoxic-
ity of all drugs, these results have been omitted from Table 4. 
Although some of those drugs (BCNU, VBL, 5-FU, and MTX) 
were solely capable of inducing a ∼50% growth reduction, 
little improvements in their cytotoxic activity were observed 
with PDF, except for a ∼90% cell viability reduction with the 
BCNU/PDF combination. No significant growth/viability 
reduction was yet seen with VP-16, CPL, CyP, or Mit.C alone 
or in combination with PDF in 72 h. Nevertheless, the PDF/VC 
combination certainly induced 90% cell viability reduction, 
which was far better than all dugs tested except BCNU. Thus, 
these results suggest that the PDF/VC combination appears 
to be more effective than various chemotherapeutic drugs 
currently being used in clinical cases. It is also possible that 
potentiation of BCNU cytotoxicity with PDF may imply its 
selective chemosensitizing effect, capable of improving the 
efficacy of certain chemotherapeutic drugs.
Possible potentiation of other natural 
agents with vC
Although no chemotherapeutic drugs seem to be potentiated 
with VC as seen above, we kept exploring if any other natural International Journal of General Medicine 2009:2 104
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products/agents besides PDF might be potentiated with VC. 
The following nine products were commercially obtained 
and used in this study:
•  ABE: Agaricus blazei Murill mushroom extract
•  HMM: Himematsutake (Iwade Strain 101) extract
•  STM: Shiitake (Lentinus edodes) mushroom extract
•  RGM: Reishi (Ganoderma lucidum) mushroom extract
•  ASC: Mixed powder of Agaricuc blazei Murill and shark 
cartilage
•  MSK: Mixed powder of three different mushrooms and 
three herbs
•  AHC: Mycelial extracts of several mushrooms
•  ARBX: Arabinoxylan from rice bran
•  YBG: Yeast cell wall extract (supplemented with vitamin C)
PC-3 cells were cultured with the varying concentra-
tions (0–1,000 µg/ml) of these extracts with or without VC 
(200 µM) and their effects on cell growth were assessed 
in 72 h. PDF (150 µg/ml) was also included serving as a 
positive control, capable of inducing 90% cell death with 
VC. Six products, such as ABE, HMM, ASC, MSK, AHC, 
and ARBX, had no effects on PC-3 cell growth even at a 
maximal dose of 1,000 µg/ml, whereas STM, RGM, and 
YBG showed ∼20%, 50%, and 90% reduction in cell 
viability, respectively (Table 5). However, it must be noted 
with caution that such profound cytotoxicity of YBG could 
have been due primarily to “VC” supplemented in this 
product. For PC-3 cells, VC by itself was found to have 
significant cytotoxic effects when its concentrations went 
beyond 500 µM (Figure 3). According to our calculation, 
we would estimate that “20 µg/ml” of YBG used to exhibit 
such potent cytotoxicity has actually contained 2400 µM 
of VC, which was apparently a lethal dose for PC-3 cells. 
It is thus feasible that YBG-induced cytotoxicity is most 
likely attributed to the excess amount of VC supplement, 
not to its active ingredient (β-glucan). Pure β-glucan 
(present in YBG) is then required for testing its cytotoxic 
effect on PC-3 cells, so that YBG has been dismissed from 
this study.
When these extracts were combined with VC (200 µM), 
most of them failed to show any enhanced cytotoxicity, except 
for STM and RGM at 150 µg/ml exhibiting ∼50% and ∼90% 
cell viability reduction, respectively (Table 5). Thus, the com-
bination of PDF and VC appears to yet have the most potent 
cytotoxic effect on PC-3 cells, inducing 90% cell viability 
reduction; however, enhanced cytotoxicity of STM and RGM 
with VC suggests that some other natural agents/products 
could be also potentiated with VC. Moreover, it should be 
noted that the effectiveness of various mushroom extracts 
(glucans or polysaccharides) is known to be cancer-specific 
despite their structural and functional similarities.68 Some 
other natural extracts besides mushrooms are also shown 
to have cancer specificity. Therefore, it cannot rule out the 
possibility that some of natural agents tested above with little 
effects could be highly effective on certain malignancies 
besides prostate cancer. Studies of those natural agents on a 
variety of cancer cells are then warranted.
Table 4 Comparison of cytotoxic effects of PDF/vC combination, chemotherapeutic drugs alone or in combination with PDF or vCa 
in PC-3 cells
Additions Cell viability (%)a Differences 
between groups
No additions PDF (150 µg/ml)
No additions 100% 100% N/Sb
+vC (200 µM) 95 ± 4.2 4.7 ± 1.3 p  0.001
+BCNU (50 µM) 48 ± 4.9 11 ± 2.7 p  0.01
+vBL (100 nM) 50 ± 5.8 50 ± 4.1 N/S
+5-FU (5 µg/ml) 53 ± 5.2 52 ± 4.7 N/S
+MTX (100 µM) 55 ± 3.6 53 ± 5.0 N/S
+vP-16 (100 nM) 100 100 N/S
+CPL (100 µM) 100 94 ± 2.0 N/S
+CyP (300 µg/ml) 100 95 ± 1.6 N/S
+Mit.C (300 nM) 100 100 N/S
Notes: aAll cell viability data (%) are mean ± SD of three separate experiments; bN/S indicates that differences in cell viability between “No additions” and “PDF” are not 
statistically significant.
Abbreviations: BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine); VBL, vinblastine; 5-FU, 5-fluorouracil; MTX, methotrexate; VP-16, etoposide; CPL, cisplatin; Cyp, 
cyclophosphamide; Mit.C, mitomycin C; PDF, Maitake D-fraction.International Journal of General Medicine 2009:2 105
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Cytotoxic effect of PDF/vC combination 
on other cancer cells
Since we have been working only on prostate cancer (PC-3) 
cells, it would be feasible to raise the question on whether the 
PDF/VC combination could be also effective on any cancers 
other than prostate cancer. This possibility was then tested using 
various human cancer cells including bladder (T24), kidney 
(ACHN), breast (MCF-7), lung (A549), stomach (AGS), liver 
(HepG2), brain (U-89), and leukemia (HL-60) cells. Addition-
ally, as it was of interest to examine possible effects of PDF/VC 
combination on “nonhuman” cancers, three canine cancer cells 
such as mammary gland (CF33), connective tissue (CF21), and 
lymphoma (CL-1) cells were also included in this study.
PDF/vC effects on human cancer cells
All human cancer cells were cultured with the varying con-
centrations (0–1,000 µg/ml) of PDF alone or in combination 
with VC (200 µM) for 24 to 72 h. Cell number/viability 
was determined at specified times and summarized in 
Table 6. No effects on ACHN, A549, and AGS cells were 
detected even with 1,000 µg/ml of PDF in 72 h, while 
some but insignificant (∼10%) growth inhibition was seen 
in both MCF-7 and HepG2 cells with PDF (1,000 µg/ml). 
In contrast, PDF demonstrated its cytotoxic effect on T24, 
U-87, and HL-60 cells. T24 cells showed nearly 50% and 
complete cell death in 72 h with 500 and 1,000 µg/ml PDF, 
respectively. Almost 90% growth inhibition (without cell 
death) was attained in U-87 cells with 250 µg/ml PDF in 
72 h, while 90% growth inhibition was achieved with 
500 µg/ml PDF in only 24 h. Nearly 50% and 90% of 
HL-60 cells were dead in 24 h with 250 and 500 µg/ml 
PDF, respectively. Thus, PDF may exhibit antiproliferative 
or cytotoxic activity in a cancer-specific manner: overall, 
PDF indeed demonstrated its cellular effects on five of eight 
human cancer cells tested.
These cancer cells were next cultured with the combination 
of PDF (150 µg/ml) and VC (200 µM) for 24 h to assess their 
responses (if any) or susceptibility to this specific regimen 
(established for PC-3 cells). Our pilot study already confirmed 
that 200 µM VC alone had no effects on all eight cancer cells 
used here. Table 6 also shows that no effects of this PDF/VC 
combination were seen in the same three cancer cells such as 
ACHN, A549, and AGS cells; however, a ∼50% growth inhi-
bition was now induced in MCF-7 and HepG2 cells with this 
combination. On the other hand, T24, U-87, and HL-60 cells 
all resulted in almost complete cell death (95%) following 
the PDF/VC treatment. Thus, these results show that T24, 
U-87, and HL-60 cells seem to be rather vulnerable to the 
PDF/VC combination just as PC-3 cells, while MCF-7 and 
HepG2 cells may have some susceptibility. The rest of three 
cancer cells show little responses to this combination regimen. 
Table 5 effects of various natural agents and their combination 
with vC on PC-3 cells
Natural agents Cell growth/viability (%)
No additions +VC (200 µM)
ABe 100% 100%
HMM 100 100
STMa ∼80 ∼50
rGMa ∼47 ∼10
ASC 100 100
MSK 100 100
AHC 100 100
ArBX 100 100
YBGb 5 N/A
PDF 100 ∼10
Notes: aFive hundred µg/ml each of STM and rGM was used solely while 150 µg/ml 
each of these agents (in comparison with PDF) was used for vC (200 µM) combina-
tion study, but this vC alone had no effects. For the rest of agents (excluding YBG), a 
maximum concentration of 1,000 µg/ml was tested solely and in combination with 
vC; bConcentration of  YBG used here was 20 µg/ml based on the amount of β-glucan, 
but it also contained the estimated, lethal dose of 2,400 µM   vC. Accordingly, YBG has 
been dismissed from this study and see the text for further explanation.
Abbreviations: ABe, Agaricus blazei Murill mushroom extract; HMM, Himematsutake 
(Iwade Strain 101) extract; STM, Shiitake (Lentinus edodes) mushroom extract; rGM, 
reishi (Ganoderma lucidum) mushroom extract; ASC, Mixed powder of Agaricuc blazei 
Murill and shark cartilage; MSK, Mixed powder of 3 different mushrooms and 3 herbs; 
AHC, Mycelial extracts of several mushrooms; ArBX, Arabinoxylan from rice bran; 
YBG, Yeast cell wall extract; N/A, not applicable.
Table 6 effects of PDF alone and its combination with  vC on various 
cancer cells
Cancer cells Growth inhibition (%)
+ PDFa +PDF/VCb
T24 (bladder) ∼50% CD with PDF (500 µg/ml) 95% CD
95% CD with PDF (1,000)
ACHN (kidney) N/e N/e
MCF-7 (breast) ∼10% GI with PDF (1,000) ∼50% GI
A549 (lung) N/e N/e
AGS (gastric) N/e N/e
HepG2 (liver) ∼10% GI with PDF (1,000) ∼50% GI
U-87 (brain) ∼90% GI with PDF (250) 95% CD
90% GI with PDF (500)
HL-60 (leukemia) ∼50% CD with PDF (250) 95% CD
∼90% CD with PDF (500)
Notes: aeffective concentrations of PDF tested (0–1,000 µg/ml) are shown; bCombination 
of PDF (150 µg/ml) and vC (200 µM) was tested, but this vC alone had no effects.
Abbreviations: CD, cell death; GI, growth inhibition; N/e, no effects; PDF, Maitake 
D-fraction.International Journal of General Medicine 2009:2 106
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These findings further suggest that the PDF/VC combination 
(as well as PDF alone) appears to somewhat act in a cancer-
specific manner.
PDF/vC effects on canine cancer cells
Three types of canine cancer cells, canine mammary gland 
cancer (CF33), connective tissue cancer (CF21), and lymphoma 
(CL-1) cells,69 were cultured with varying concentrations 
(0–1,000 µg/ml) of PDF alone or in combination with VC 
(200 µM), and cell number/viability was assessed at specified 
times. The results are then summarized in Table 7. In 72 h, 
500 and 1,000 µg/ml of PDF led to ∼40% and ∼65% growth 
reduction in CF33 cells while ∼30% and ∼70% growth reduc-
tion in CF21 cells, respectively. In contrast, CL-1 cells appeared 
to be more susceptible to PDF, because ∼20% and 90% of 
these cells were dead in 24 h with 500 and 1,000 µg/ml PDF, 
respectively. Thus, PDF seems to induce the growth inhibition 
or cell death in all three canine cancer cells, although it would 
require the relatively high concentrations (500 or 1,000 µg/ml) 
of PDF to be effective.
When these cancer cells were cultured with the combina-
tion of PDF (150 µg/ml) and VC (200 µM) for 24 h, both 
CF33 and CF21 cells showed a ∼90% growth reduction while 
all CL-1 cells were found to be completely dead (Table 7). 
Taken together, PDF alone or its combination with VC dem-
onstrates significant antiproliferative or cytotoxic activity on 
three canine cancer cells, implying that PDF may work on 
human cancers as well as canine and other veterinary cancers 
crossing a species barrier.
Conclusions
A number of in vitro and in vivo studies and limited clinical 
studies have demonstrated potent immunomodulatory and 
antitumor activities of PDF or Maitake D-fraction, implying its 
great potential in cancer treatment and prevention. Particularly 
synergistic potentiation of PDF with VC may further help 
improve the efficacy of currently ongoing treatments for various 
cancers. Although iv administration of VC could be an inter-
esting and useful procedure, more clinical studies are required 
for assessing its safety and efficacy in cancer patients. It is also 
interesting that PDF may not only alleviate various side effects 
and improve quality of life of patients under chemotherapy but 
also have possible chemosensitizing effect to improve the effi-
cacy of chemotherapy. However, as more comprehensive and 
controlled studies are required for the clinical demonstration 
of PDF, the active participation of physicians and professional 
health care providers in such studies is advised to properly and 
timely evaluate PDF for cancer therapy.
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